/DaVita%20Inc%20location-%20by%20sanfel%20via%20iStock.jpg)
With a market cap of $11.7 billion, DaVita Inc. (DVA) provides kidney dialysis and related laboratory services for patients with chronic kidney failure, primarily through outpatient centers. It also offers integrated care, clinical research, physician services, and comprehensive kidney care, including home-based and hospital dialysis options.
Shares of the Denver, Colorado-based company have surpassed the broader market over the past 52 weeks. DVA stock has soared 43.4% over this time frame, while the broader S&P 500 Index ($SPX) has gained 21.7%. Moreover, the stock has climbed 62.8% on a YTD basis, compared to SPX's 13.3% rise.
Looking closer, shares of the kidney dialysis provider have also outpaced the State Street Health Care Select Sector SPDR ETF's (XLV) 30% increase over the past 52 weeks.
DaVita has outperformed due to strong execution across its Integrated Kidney Care platform, rising patient treatment volumes, and resilient demand for essential dialysis services.
However, the stock tumbled 17.2% following its Q2 2026 results on Aug. 4 as investors focused on weaker revenue per treatment, which declined to $415.87, driven by lower dialysis enrollment following the loss of pandemic-era ACA subsidies and reduced phosphate-binder revenue. Although Q2 adjusted EPS of $4.02 beat the estimate and revenue of $3.55B was broadly in line with the consensus, the company’s reaffirmed 2026 adjusted EPS outlook of $14.10 - $15.20 remained below the analyst midpoint/consensus expectation. Concerns were further amplified by the expected ACA subsidy impact of approximately $40 million in 2026 and $70 million in 2027, signaling continued pressure on treatment volumes and revenue.
For the fiscal year ending in December 2026, analysts expect DaVita’s adjusted EPS to grow 35.2% year-over-year to $14.57. The company's earnings surprise history is mixed. It topped the consensus estimates in three of the last four quarters while missing on another occasion.
Among the eight analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on three “Strong Buy” ratings, four “Holds,” and one “Moderate Sell.”
This configuration has remained unchanged over the past three months.
On Aug. 5, Barclays analyst Andrew Mok raised DaVita’s price target to $224 and maintained an “Equal Weight” rating.
The mean price target of $230.28 represents a nearly 27% premium to DVA’s current price levels. The Street-high price target of $270 implies a potential upside of 48.8%.
